Clinical trials: Uterine Cervical Cancer
Recurrent Cervical Cancer, Metastatic Cervical Cancer
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated…
- Trial name
- NCT04380805
- Testing
- AK104
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Akeso
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
- Trial name
- NCT04630353
- Testing
- HB-201 IV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Recurrent or Metastatic Cervical Cancer
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN033 versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have…
- Trial name
- NCT07797153
- Testing
- JSKN033, Docetaxel, Topotecan
- Where
- 2 sites in China
- Volunteers
- 368 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Protocol V503-021 is a long-term follow-up study of the V503-001 base study (NCT00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of V503 vaccine in preventing cervical cancer and related precancers…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT02653118
- Testing
- V503, GARDASIL
- Volunteers
- 4,453 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP)…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- REVEAL 1 (NCT03185013)
- Testing
- VGX-3100, Electroporation (EP)
- Where
- 60 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Inovio Pharmaceuticals
Lung Cancer, Colon Cancer
A Study of PHN-010 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
- Conditions
- Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT06457997
- Testing
- PHN-010
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Pheon Therapeutics
Cervical Cancer
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic…
- Trial name
- SKYSCRAPER-04 (NCT04300647)
- Testing
- Tiragolumab, Atezolizumab
- Where
- 58 sites in United States, Australia and 15 more
- Volunteers
- 172 people
- Sponsor
- Hoffmann-La Roche
HPV-Related Cervical Carcinoma, HPV-Related Malignancy
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or after treatment with the first-line standard of care (pembrolizumab with…
- Conditions
- HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
- Trial name
- NCT06099418
- Testing
- VB10.16, Atezolizumab Injection [Tecentriq]
- Sponsor
- Nykode Therapeutics ASA
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of NEO-201 in Solid Tumors Expansion Cohorts
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
- Trial name
- NCT03476681
- Testing
- NEO-201 in combination with pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- Precision Biologics, Inc
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.
Cervical Cancer
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based…
- Trial name
- NCT03635567
- Testing
- Pembrolizumab, Paclitaxel, Cisplatin
- Where
- 149 sites in United States, Argentina and 17 more
- Volunteers
- 617 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Cervical Cancer
Biop System's Safety and Performance
Biop system's safety and performance in increased detection of High-Grade lesions of the cervical epithelium in women scheduled for colposcopy
- Trial name
- NCT04232865
- Testing
- Biop System
- Volunteers
- 320 people
- Sponsor
- BIOP Medical
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.